Form 4: Cue Biopharma Director, Pamela Garzone, Awarded Stock Options

Pamela Garzone, a director at Cue Biopharma, was granted stock options for 24,400 shares on January 2, 2025, according to a Form 4 filing.

Summary

• Pamela Garzone, a director of Cue Biopharma, Inc., was granted stock options to purchase 24,400 shares of common stock.
• The options were granted on January 2, 2025, with an exercise price of $1.09 per share.
• The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the first anniversary.
• The options expire on January 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a standard compensation practice. The grant of options is generally viewed as a positive, but it's a routine event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Cue Biopharma's director compensation to that of similar-sized companies like Iovance Biotherapeutics or Adaptimmune Therapeutics would provide a better understanding of its competitiveness.
• Typical director compensation packages include a mix of cash retainers, meeting fees, and equity awards.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates